29 protocols found



Protocol No. Title Status
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Open
UW19048 A Phase II Trial Of Tisagenlecleucel In First-Line High-Risk (HR) Pediatric And Young Adult Patients With B-Cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive At The End Of Consolidation (EOC) Therapy, AALL1721 Open
AGCT1532 A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors Open
UW18086 A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine versus Observation in Patients who Achieve a Chemotherapy-induced Remission Open
A041702 A Randomized Phase III Study of Ibrutinib plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzmab in Untreated Older Patients (>/= 70 YEARS OF AGE) with Chronic Lymphocytic Leukemia (CLL) Open
EA9161 A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Open
UW16061 A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin s Lymphoma (NHL), and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL Open
AAML18P1 AAML18P1, Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW16144 An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) Open
BMTCTN1703/1801 BMTCTN1703: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation BMTCTN1801: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune) Open
BMTCTN1702 Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D) Open
BMTCTN1704 Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM) Open
UW15106 Genomic Analysis of Long-Term Survivors with Metastatic Cancer Open
AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621C NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tazemetostat in Patients with tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621I NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes Open
ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer Open
APEC14B1 Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study Open
UW19082 Symptom Burden, Co-Occurrence, and Trajectories in Children with Advanced Cancer Open
ACCL1633 The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open